Comment on

• Oncological Long-term Outcome After Whole-gland High-intensity Focused Ultrasound for Prostate Cancer-21-yr Follow-up.

  Bründl J, Osberghaus V, Zeman F, Breyer J, Ganzer R, Blana A, Gierth M, Denzinger S, Burger M, Rosenhammer B. Bründl J, et al. Eur Urol Focus. 2022 Jan;8(1):134-140. doi: 10.1016/j.euf.2020.12.016. Epub 2021 Jan 20. Eur Urol Focus. 2022. PMID: 33483288
• Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.

  Li H, Zhang Y, Li D, Ma X, Xu K, Ding B, Li H, Wang Z, Ouyang W, Long G, Zeng J, Liu H, Yan L, Zhang Y, Liu Z, Guan W, Hu Z, Liu C, Wan J, Wang G, Pu X, Zhang M, Guo L, An R, Qi J, Guo A, Ye Z, Liu J, Zhang X, Xu H. Li H, et al. Eur Urol. 2021 Jun;79(6):879-886. doi: 10.1016/j.eururo.2021.01.037. Epub 2021 Feb 10. Eur Urol. 2021. PMID: 33579577
• Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.

  Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE. Pasalic D, et al. Cancer. 2021 Jun 1;127(11):1912-1925. doi: 10.1002/cncr.33388. Epub 2021 Feb 17. Cancer. 2021. PMID: 33595853